Olga Victoria Gomez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olga Victoria Gomez has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Africa Pertierra Cortada
Neonatology Department, BCNatal—Centre de Medicina Maternofetal i Neonatologia de Barcelona, Hospital Sant Joan de Déu, Universitat de Barcelona, 08950 Barcelona, Spain
1 shared publication - Akshay B. Jain
University of British Columbia, Vancouver, British Columbia
1 shared publication - Anne Debeer
Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium
1 shared publication - Camilo Alberto González González
Departamento de Medicina Interna, Unidad de Nefrología Hospital Universitario San Ignacio Bogotá Colombia
1 shared publication - David Basurto
Department of Development and Regeneration, Cluster Woman and Child, Biomedical Sciences, My FetUZ Fetal Research Center, KU Leuven, Leuven, Belgium
1 shared publication - David C. Klonoff
Sutter Health Research Institute, Emeryville, CA, USA
1 shared publication
Latest Publications
- Open Access
- 3 April 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (4) , 682-699
Advance Insulin Injection Technique and Education With FITTER Forward Expert Recommendations
- 3 April 2025
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 100 (4) , 682-699
Open AccessAdvance Insulin Injection Technique and Education With FITTER Forward Expert Recommendations
- 20 July 2022
- Published by Wiley in Prenatal Diagnosis
- Vol. 42 (10) , 1303-1311
Pulmonary hypertension in congenital diaphragmatic hernia: Antenatal prediction and impact on neonatal mortality
Objective: To determine the prevalence of pulmonary hypertension (PAH) in left‐sided congenital diaphragmatic hernia (CDH); how we could predict it; and how PAH contributed to the model for mortality prediction.Study Design: Retrospective analysis in three European centers. The primary outcome was the presence of PAH on postnatal day (d) 1, 7, and at discharge. Studied predictors of PAH were: observed/expected‐lung/head‐ratio (o/e LHR), liver‐herniation, fetoscopic endoluminal tracheal occlusion (FETO), and gestational age (GA) at delivery. The combined effect of pre‐ and postnatal variables on mortality was modeled by Cox regression.Results: Of the 197 neonates, 56 (28.4%) died. At d1, 67.5% (133/197) had PAH and 61.9% (101/163) by d7. Overall, 6.4% (9/141) had PAH at discharge. At d1, o/e LHR (odds ratio (OR) 0.96) and FETO (OR 2.99) independently correlated to PAH (areas under the curve [AUC]: 0.74). At d7, PAH significantly correlated only with the use of FETO (OR 3.9; AUC: 0.65). None were significant for PAH at discharge. Combining the occurrence of PAH with antenatal biomarkers improved mortality prediction (p = 0.02), in a model including o/e LHR (HR: 0.94), FETO (HR: 0.35), liver herniation (HR: 16.78), and PAH (HR: 15.95).Conclusions: Antenatal prediction of PAH was only moderate. The postnatal occurrence of PAH further increases the risk of death. Whereas this may be used to counsel parents in the postnatal period, our study demonstrates there is a need to find more accurate antenatal predictors for PAH.
- 20 July 2022
- Published by Wiley in Prenatal Diagnosis
- Vol. 42 (10) , 1303-1311
Pulmonary hypertension in congenital diaphragmatic hernia: Antenatal prediction and impact on neonatal mortality
Objective: To determine the prevalence of pulmonary hypertension (PAH) in left‐sided congenital diaphragmatic hernia (CDH); how we could predict it; and how PAH contributed to the model for mortality prediction.Study Design: Retrospective analysis in three European centers. The primary outcome was the presence of PAH on postnatal day (d) 1, 7, and at discharge. Studied predictors of PAH were: observed/expected‐lung/head‐ratio (o/e LHR), liver‐herniation, fetoscopic endoluminal tracheal occlusion (FETO), and gestational age (GA) at delivery. The combined effect of pre‐ and postnatal variables on mortality was modeled by Cox regression.Results: Of the 197 neonates, 56 (28.4%) died. At d1, 67.5% (133/197) had PAH and 61.9% (101/163) by d7. Overall, 6.4% (9/141) had PAH at discharge. At d1, o/e LHR (odds ratio (OR) 0.96) and FETO (OR 2.99) independently correlated to PAH (areas under the curve [AUC]: 0.74). At d7, PAH significantly correlated only with the use of FETO (OR 3.9; AUC: 0.65). None were significant for PAH at discharge. Combining the occurrence of PAH with antenatal biomarkers improved mortality prediction (p = 0.02), in a model including o/e LHR (HR: 0.94), FETO (HR: 0.35), liver herniation (HR: 16.78), and PAH (HR: 15.95).Conclusions: Antenatal prediction of PAH was only moderate. The postnatal occurrence of PAH further increases the risk of death. Whereas this may be used to counsel parents in the postnatal period, our study demonstrates there is a need to find more accurate antenatal predictors for PAH.
- Open Access
- 1 March 2022
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 9 (2)
GLP-1Ra en el manejo de diabetes mellitus tipo 2: una revisión de revisiones sistemáticas
Introduction: Diabetes mellitus is a serious chronic disease with a worldwide prevalence of 8.5% in people over 18 years of age, of which 90% belong to type 2; A pharmacological option for its management is GLP-1Ra, which has an efficacy in reducing glycosylated hemoglobin (HbA1c) of 0.9 to 1.6%. Aim: To synthesize the evidence from systematic reviews on the safety of GLP-1Ra for cardiovascular and renal outcomes compared with standard therapy in adult patients with T2DM and the reported effectiveness. Methods: A comprehensive and systematic literature search was performed on Medline and Ovid with complementary search methods. Data selection and extraction was independent and paired. The methodological quality was evaluated with SING. The following were evaluated as intervention: Liraglutide, Lixisenatide, Albiglutide, Semaglutide, Dulaglutide, Exenatide, Taspoglutide and Efpeglenatide compared with placebo or active therapy. Results: Seventeen studies were included, which grouped 47 unique clinical trials. The results show a trend in the protective effect for cardiovascular and renal outcomes, but very few analyses show to be statistically significant when the molecules are analyzed individually, also reporting contradictions in the direction of the effect for some cardiovascular outcomes. Conclusions: The results should be interpreted with caution given the variability and contradiction in the direction of the effect in some cases. We suggest to decide their use in clinical practice according to the baseline characteristics of the patients and the individual safety results of each molecule. Introducción: La diabetes mellitus es una enfermedad crónica grave con una prevalencia mundial del 8.5% en mayores de 18 años, de los cuales el 90% pertenecen al tipo 2; una opción farmacológica para su manejo son los GLP-1Ra, los cuales tienen una eficacia en la reducción de la hemoglobina glicosilada (HbA1c) de 0.9 hasta el 1.6%. Objetivo: Sintetizar la evidencia de revisiones sistemáticas sobre la seguridad de los GLP-1Ra para desenlaces cardiovasculares y renales comparada con terapia estándar en pacientes adultos con DMT-2 y la efectividad reportada. Métodos: Se realizó una búsqueda amplia y sistemática de literatura en Medline y Ovid con métodos complementarios de búsqueda. La selección y extracción de datos fue independiente y pareada. La calidad metodológica fue evaluada con SING. Como intervención se evaluaron: Liraglutida, Lixisenatida, Albiglutida, Semaglutida, Dulaglutida, Exenatida, Taspoglutida y Efpeglenatida comparado con placebo o terapia activa. Resultados: Diecisiete estudios fueron incluidos, los cuales agruparon 47 ensayos clínicos únicos. Los resultados muestran una tendencia en el efecto protector para los desenlaces cardiovasculares y renales, pero muy pocos muestran ser estadísticamente significativos cuando se analizan individualmente las moléculas en los que también se reportan contradicciones en la dirección del efecto para algunos desenlaces cardiovasculares. Conclusiones: Los resultados deben ser interpretados con cautela daba la variabilidad y contradicción en la dirección del efecto en algunos casos. Su uso en la práctica clínica se sugiere esté orientado por las características basales de los pacientes y los resultados individuales de seguridad de cada molécula.
- 1 March 2022
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 9 (2)
Open AccessGLP-1Ra en el manejo de diabetes mellitus tipo 2: una revisión de revisiones sistemáticas
Introduction: Diabetes mellitus is a serious chronic disease with a worldwide prevalence of 8.5% in people over 18 years of age, of which 90% belong to type 2; A pharmacological option for its management is GLP-1Ra, which has an efficacy in reducing glycosylated hemoglobin (HbA1c) of 0.9 to 1.6%. Aim: To synthesize the evidence from systematic reviews on the safety of GLP-1Ra for cardiovascular and renal outcomes compared with standard therapy in adult patients with T2DM and the reported effectiveness. Methods: A comprehensive and systematic literature search was performed on Medline and Ovid with complementary search methods. Data selection and extraction was independent and paired. The methodological quality was evaluated with SING. The following were evaluated as intervention: Liraglutide, Lixisenatide, Albiglutide, Semaglutide, Dulaglutide, Exenatide, Taspoglutide and Efpeglenatide compared with placebo or active therapy. Results: Seventeen studies were included, which grouped 47 unique clinical trials. The results show a trend in the protective effect for cardiovascular and renal outcomes, but very few analyses show to be statistically significant when the molecules are analyzed individually, also reporting contradictions in the direction of the effect for some cardiovascular outcomes. Conclusions: The results should be interpreted with caution given the variability and contradiction in the direction of the effect in some cases. We suggest to decide their use in clinical practice according to the baseline characteristics of the patients and the individual safety results of each molecule. Introducción: La diabetes mellitus es una enfermedad crónica grave con una prevalencia mundial del 8.5% en mayores de 18 años, de los cuales el 90% pertenecen al tipo 2; una opción farmacológica para su manejo son los GLP-1Ra, los cuales tienen una eficacia en la reducción de la hemoglobina glicosilada (HbA1c) de 0.9 hasta el 1.6%. Objetivo: Sintetizar la evidencia de revisiones sistemáticas sobre la seguridad de los GLP-1Ra para desenlaces cardiovasculares y renales comparada con terapia estándar en pacientes adultos con DMT-2 y la efectividad reportada. Métodos: Se realizó una búsqueda amplia y sistemática de literatura en Medline y Ovid con métodos complementarios de búsqueda. La selección y extracción de datos fue independiente y pareada. La calidad metodológica fue evaluada con SING. Como intervención se evaluaron: Liraglutida, Lixisenatida, Albiglutida, Semaglutida, Dulaglutida, Exenatida, Taspoglutida y Efpeglenatida comparado con placebo o terapia activa. Resultados: Diecisiete estudios fueron incluidos, los cuales agruparon 47 ensayos clínicos únicos. Los resultados muestran una tendencia en el efecto protector para los desenlaces cardiovasculares y renales, pero muy pocos muestran ser estadísticamente significativos cuando se analizan individualmente las moléculas en los que también se reportan contradicciones en la dirección del efecto para algunos desenlaces cardiovasculares. Conclusiones: Los resultados deben ser interpretados con cautela daba la variabilidad y contradicción en la dirección del efecto en algunos casos. Su uso en la práctica clínica se sugiere esté orientado por las características basales de los pacientes y los resultados individuales de seguridad de cada molécula.